Eli Lilly has launched its oral GLP-1 drug Foundayo in the UK, marking an important expansion of the pharmaceutical company’s weight-management business into the European market. The launch comes as demand for obesity treatments continues to grow and pharmaceutical companies compete to develop alternatives to injectable therapies that could broaden access to a rapidly expanding market.

Foundayo Enters the UK Weight-Loss Market

Foundayo, whose active ingredient is orforglipron, became available in the UK following authorization by the country’s Medicines and Healthcare products Regulatory Agency on August 10. The treatment is approved for weight management in adults with obesity or certain adults who are overweight and have weight-related medical conditions, as well as for improving blood-sugar control in patients with inadequately controlled type 2 diabetes.

The drug is being launched through private prescriptions rather than the UK’s National Health Service at this stage. Eli Lilly is working with the National Institute for Health and Care Excellence on a potential future rollout through the NHS, which could significantly broaden the treatment’s potential patient base if it receives favorable cost-effectiveness consideration.

Foundayo is designed to be taken once daily and does not require patients to coordinate the dose with meals or water intake. That convenience could become an important competitive factor as patients and healthcare providers increasingly evaluate oral alternatives to injectable GLP-1 medicines.

Pricing and Convenience Could Shape Demand

Eli Lilly expects Foundayo to be priced at approximately £100 to £120 for a month’s supply in the UK, significantly below the reported £330 monthly price of Mounjaro. The lower price does not necessarily indicate a lower-value treatment, but it could make oral therapy more accessible within the private healthcare market.

Clinical data have shown that Foundayo can produce meaningful weight reductions when combined with a reduced-calorie diet and increased physical activity. At the highest approved dose of 17.2 milligrams, patients without diabetes recorded average weight loss of 11.1% after 72 weeks in a Phase 3 study, compared with 2.1% for placebo.

The treatment’s oral format could also address one of the practical barriers associated with injectable medicines. However, the market will continue to assess efficacy, tolerability, long-term adherence and pricing alongside convenience.

Competition With Novo Nordisk Is Intensifying

The UK launch places Lilly directly against Novo Nordisk in the emerging market for oral GLP-1 treatments. Novo’s Wegovy pill was cleared in Britain in June, making Foundayo the second oral GLP-1 weight-loss treatment authorized in the country.

The competition is strategically important because the obesity-drug market has historically been dominated by injectable treatments. A successful transition toward oral medicines could expand the overall treatment population while forcing pharmaceutical companies to compete more heavily on convenience, efficacy, pricing and access.

For Eli Lilly, the UK launch also provides an early opportunity to establish Foundayo in a major European healthcare market while regulatory reviews continue elsewhere in the region. Investors will be watching private-market demand, pricing, NHS negotiations and the pace of regulatory decisions in Europe. The ability of Foundayo to complement Lilly’s existing Mounjaro and broader metabolic-health portfolio will be important in determining how much incremental growth the oral treatment can generate as competition in the GLP-1 market intensifies.